Adverse childhood experiences are common in children with systemic lupus erythematosus and are linked to higher odds of ...

Single dose treatment of FT819 without conditioning chemotherapy achieves lupus low disease activity state (LLDAS) in active SLE Patients; ...

Several cars travelling along the Seletar Expressway (SLE) had a close call on Saturday (May 9) morning after some loose ...

Obexelimab Phase 3 win, SLE catalyst, pipeline updates (ZB014, orelabrutinib), and cash runway—read now. Click for a ZBIO ...

The FDA has approved Saphnelo (anifrolumab-fnia) for subcutaneous administration in patients with systemic lupus ...

Dose-response signal appears in phase II trial, and all doses are better than placebo ...

The approval is supported by results from the Phase III TULIP-SC trial.

The police said the lorry driver left the scene before they arrived. Read more at straitstimes.com. Read more at straitstimes ...

Climb Bio (NASDAQ:CLYM) used an investor R&D spotlight event to outline its strategy around CD19-targeted B-cell depletion ...

Children with rheumatic diseases frequently experience unmet social needs, with the highest rates reported by those with SLE or JDM.

The FDA has approved Saphnelo (anifrolumab-fnia) for subcutaneous administration in patients with systemic lupus ...

The reset in analyst assumptions has taken Super League Enterprise’s fair value target from $52.00 to $14.50, a sharp change that reframes how you might think about potential upside. Analysts link ...